Metastatic melanoma is advanced melanoma with dissemination to distant skin, lymph node, lung, liver, bone, and brain sites. The metastatic phenotype is strongly shaped by MAPK pathway activation through BRAF, NRAS, and NF1 alterations, transcriptional plasticity, immune escape through PD-1/PD-L1 and related checkpoints, and pronounced brain tropism in advanced disease.
Ask a research question about Metastatic Melanoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Metastatic Melanoma
creation_date: '2026-03-28T21:05:00Z'
updated_date: '2026-05-10T07:56:24Z'
description: >-
Metastatic melanoma is advanced melanoma with dissemination to distant skin,
lymph node, lung, liver, bone, and brain sites. The metastatic phenotype is
strongly shaped by MAPK pathway activation through BRAF, NRAS, and NF1 alterations,
transcriptional plasticity, immune escape through PD-1/PD-L1 and related checkpoints,
and pronounced brain tropism in advanced disease.
categories:
- Skin Cancer
- Metastatic Cancer
- Solid Tumor
parents:
- cutaneous melanoma
disease_term:
preferred_term: metastatic melanoma
term:
id: MONDO:0005012
label: cutaneous melanoma
mappings:
mondo_mappings:
- term:
id: MONDO:0005012
label: cutaneous melanoma
mapping_predicate: skos:closeMatch
mapping_source: MONDO
mapping_justification: Closest MONDO parent term available for metastatic melanoma.
prevalence:
- population: Advanced melanoma with brain metastasis
percentage: 60
notes: Melanoma brain metastases affect up to 60% of advanced melanoma cases.
evidence:
- reference: PMID:40609368
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Melanoma brain metastases (MBM) affect up to 60 % of advanced melanoma cases and are associated with poor prognosis and significant neurologic morbidity.
explanation: This provides a direct estimate for the burden of brain dissemination in advanced melanoma.
- population: Advanced melanoma treated with nivolumab
percentage: 34.2
notes: Estimated 5-year survival in a heavily pretreated advanced melanoma cohort.
evidence:
- reference: PMID:31343665
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Overall survival curves showed estimated 5-year rates of 34.2% among patients with melanoma, 27.7% among patients with RCC, and 15.6% among patients with NSCLC.
explanation: This provides a 5-year survival benchmark in advanced melanoma.
pathophysiology:
- name: MAPK-Driven Metastatic Fitness
description: >-
Activating BRAF and NRAS mutations, together with NF1 loss, sustain MAPK signaling
that promotes proliferation, invasion, therapy resistance, and metastatic competence.
These drivers remain central even as melanoma cells transition between proliferative
and invasive transcriptional states.
evidence:
- reference: PMID:40023845
supports: SUPPORT
evidence_source: IN_VITRO
snippet: Hotspot BRAF, hotspot NRAS, and NF1 loss-of-function mutations are found in approximately 50%, 25%, and 15% of cutaneous melanomas, respectively.
explanation: This supports the dominant mutational architecture underlying metastatic melanoma biology.
biological_processes:
- preferred_term: MAPK cascade
modifier: INCREASED
term:
id: GO:0000165
label: MAPK cascade
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
- name: Invasive Plasticity and Migration
description: >-
Melanoma cells toggle between differentiated and invasive states, enabling tissue
invasion, vascular entry, and colonization of distant organs. This phenotype is
supported by EMT-like programs even in a non-epithelial lineage and is strongly
linked
to brain and visceral dissemination.
biological_processes:
- preferred_term: epithelial to mesenchymal transition
modifier: INCREASED
term:
id: GO:0001837
label: epithelial to mesenchymal transition
- preferred_term: cell migration
modifier: INCREASED
term:
id: GO:0016477
label: cell migration
- preferred_term: positive regulation of cell migration
modifier: INCREASED
term:
id: GO:0030335
label: positive regulation of cell migration
- name: PD-L1-Mediated Immune Escape
description: >-
PD-L1 expression and checkpoint signaling permit metastatic melanoma cells to
evade
cytotoxic T-cell killing. This immune escape program shapes metastatic site behavior
and contributes to heterogeneous responses across cerebral and extracerebral lesions.
evidence:
- reference: PMID:25788491
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Programmed death ligand-1 (PD-L1) tumor expression represents a mechanism of immune escape for melanoma cells.
explanation: This directly supports PD-L1-mediated immune evasion in metastatic melanoma.
biological_processes:
- preferred_term: negative regulation of immune response
modifier: INCREASED
term:
id: GO:0050777
label: negative regulation of immune response
- name: Brain Metastatic Colonization
description: >-
Melanoma has marked neurotropism, and brain metastases arise through blood-brain
barrier
traversal, adaptation to the neural microenvironment, and coordination of targeted
and
immune resistance programs. Brain lesions are a major cause of neurologic morbidity.
evidence:
- reference: PMID:40609368
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Melanoma brain metastases (MBM) affect up to 60 % of advanced melanoma cases and are associated with poor prognosis and significant neurologic morbidity.
explanation: This supports brain tropism as a defining feature of advanced melanoma.
biological_processes:
- preferred_term: cell migration
modifier: INCREASED
term:
id: GO:0016477
label: cell migration
- name: Angiogenic Support of Distant Lesions
description: >-
Melanoma metastases require angiogenic remodeling to sustain outgrowth in visceral
and
cerebral sites, with vascular permeability and local neovascularization supporting
both
tumor expansion and treatment resistance.
biological_processes:
- preferred_term: angiogenesis
modifier: INCREASED
term:
id: GO:0001525
label: angiogenesis
phenotypes:
- category: Neurologic
name: Headache
frequency: FREQUENT
description: Headache is common in melanoma brain metastases and often reflects edema or intracranial mass effect.
phenotype_term:
preferred_term: Headache
term:
id: HP:0002315
label: Headache
- category: Neurologic
name: Seizure
frequency: OCCASIONAL
description: Seizures occur with cortical brain metastases and hemorrhagic lesions.
phenotype_term:
preferred_term: Seizure
term:
id: HP:0001250
label: Seizure
- category: Musculoskeletal
name: Bone pain
frequency: OCCASIONAL
description: Bone metastases cause focal pain and skeletal fragility.
phenotype_term:
preferred_term: Bone pain
term:
id: HP:0002653
label: Bone pain
- category: Constitutional
name: Weight loss
frequency: FREQUENT
description: Progressive metastatic melanoma often causes systemic weight loss and cachexia.
phenotype_term:
preferred_term: Weight loss
term:
id: HP:0001824
label: Weight loss
- category: Constitutional
name: Fatigue
frequency: VERY_FREQUENT
description: Fatigue reflects inflammatory burden, treatment effects, and advanced disease.
phenotype_term:
preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
genetic:
- name: BRAF
association: Somatic activating mutation
notes: BRAF V600 alterations are major drivers of metastatic melanoma and support dependence on MAPK signaling.
- name: NRAS
association: Somatic activating mutation
notes: NRAS mutations promote MAPK and PI3K pathway activation and contribute to invasive plasticity.
- name: NF1
association: Somatic loss of function
notes: NF1 loss releases RAS signaling and can increase PD-L1 expression and immune evasion.
- name: PTEN
association: Somatic loss of function
notes: PTEN loss augments PI3K-AKT signaling and is associated with aggressive metastatic behavior.
environmental:
- name: Ultraviolet radiation exposure
notes: Ultraviolet mutagenesis drives many primary melanomas and establishes the mutational landscape later selected during metastasis.
notes: >-
Requested NCIT cross-reference: NCIT:C8925. This entry uses MONDO:0005012
(cutaneous melanoma) as the structured disease term because the schema
natively supports MONDO disease mappings. Brain metastasis, PD-L1-mediated
immune escape, and BRAF/NRAS/NF1 MAPK signaling are dominant features of the
metastatic state.
treatments:
- name: Ipilimumab Plus Nivolumab Checkpoint Blockade
description: Combined CTLA-4 and PD-1 checkpoint blockade is used for metastatic melanoma, including patients with asymptomatic brain metastases, to enhance antitumor T-cell priming and effector activity.
treatment_term:
preferred_term: immunotherapy
term:
id: NCIT:C15262
label: Immunotherapy
therapeutic_agent:
- preferred_term: nivolumab
term:
id: NCIT:C68814
label: Nivolumab
- preferred_term: ipilimumab
term:
id: CHEBI:231679
label: ipilimumab
evidence:
- reference: DOI:10.3390/cancers16142559
reference_title: Efficacy of Ipilimumab and Nivolumab in Patients with Melanoma and Brain Metastases—A Danish Real-World Cohort
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Combination immunotherapy using ipilimumab/nivolumab is the golden standard treatment for patients with melanoma and asymptomatic brain metastases (MBM).
explanation: The real-world cohort supports ipilimumab plus nivolumab as a standard systemic immunotherapy option in metastatic melanoma with brain metastases.
references:
- reference: DOI:10.1007/s11060-025-04951-z
title: Timing of brain metastases in relation to outcome during first-line ipilimumab plus nivolumab therapy for metastatic melanoma in a community oncology practice
found_in:
- Metastatic_Melanoma-deep-research-falcon.md
findings:
- statement: Timing of brain metastases in relation to outcome during first-line ipilimumab plus nivolumab therapy for metastatic melanoma in a community oncology practice
supporting_text: Timing of brain metastases in relation to outcome during first-line ipilimumab plus nivolumab therapy for metastatic melanoma in a community oncology practice
- reference: DOI:10.1080/14737159.2024.2347484
title: 'Prognostic biomarkers in melanoma: a 2023 update from clinical trials in different therapeutic scenarios'
found_in:
- Metastatic_Melanoma-deep-research-falcon.md
findings:
- statement: 'Prognostic biomarkers in melanoma: a 2023 update from clinical trials in different therapeutic scenarios'
supporting_text: 'Prognostic biomarkers in melanoma: a 2023 update from clinical trials in different therapeutic scenarios'
- reference: DOI:10.1093/noajnl/vdae090.044
title: IMUN-05 PHASE II STUDY OF NIVOLUMAB (NIVO) IN COMBINATION WITH RELATLIMAB (RELA) IN PATIENTS WITH ACTIVE MELANOMA BRAIN METASTASES (MBM)
found_in:
- Metastatic_Melanoma-deep-research-falcon.md
findings:
- statement: More than half of patients diagnosed with metastatic melanoma (MM) will develop brain metastases.
supporting_text: More than half of patients diagnosed with metastatic melanoma (MM) will develop brain metastases.
evidence:
- reference: DOI:10.1093/noajnl/vdae090.044
reference_title: IMUN-05 PHASE II STUDY OF NIVOLUMAB (NIVO) IN COMBINATION WITH RELATLIMAB (RELA) IN PATIENTS WITH ACTIVE MELANOMA BRAIN METASTASES (MBM)
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: More than half of patients diagnosed with metastatic melanoma (MM) will develop brain metastases.
explanation: Deep research cited this publication as relevant literature for Metastatic Melanoma.
- reference: DOI:10.1097/cm9.0000000000003416
title: Recent global patterns in skin cancer incidence, mortality, and prevalence
found_in:
- Metastatic_Melanoma-deep-research-falcon.md
findings:
- statement: Skin cancer is a common skin disease whose incidence and mortality rates have been showing yearly increases.
supporting_text: Skin cancer is a common skin disease whose incidence and mortality rates have been showing yearly increases.
evidence:
- reference: DOI:10.1097/cm9.0000000000003416
reference_title: Recent global patterns in skin cancer incidence, mortality, and prevalence
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Skin cancer is a common skin disease whose incidence and mortality rates have been showing yearly increases.
explanation: Deep research cited this publication as relevant literature for Metastatic Melanoma.
- reference: DOI:10.1097/cmr.0000000000000959
title: Global trends in cutaneous malignant melanoma incidence and mortality
found_in:
- Metastatic_Melanoma-deep-research-falcon.md
findings:
- statement: Mortality from cutaneous malignant melanoma (CMM) increased in the past, but trends have been favorable in more recent years in many high-income countries.
supporting_text: Mortality from cutaneous malignant melanoma (CMM) increased in the past, but trends have been favorable in more recent years in many high-income countries.
evidence:
- reference: DOI:10.1097/cmr.0000000000000959
reference_title: Global trends in cutaneous malignant melanoma incidence and mortality
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Mortality from cutaneous malignant melanoma (CMM) increased in the past, but trends have been favorable in more recent years in many high-income countries.
explanation: Deep research cited this publication as relevant literature for Metastatic Melanoma.
- reference: DOI:10.1186/s12885-024-12426-z
title: Patterns and trends in melanoma mortality in the United States, 1999–2020
found_in:
- Metastatic_Melanoma-deep-research-falcon.md
findings:
- statement: Melanoma, a deadly form of skin cancer, has witnessed a notable increase in incidence over the past decades.
supporting_text: Melanoma, a deadly form of skin cancer, has witnessed a notable increase in incidence over the past decades.
evidence:
- reference: DOI:10.1186/s12885-024-12426-z
reference_title: Patterns and trends in melanoma mortality in the United States, 1999–2020
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Melanoma, a deadly form of skin cancer, has witnessed a notable increase in incidence over the past decades.
explanation: Deep research cited this publication as relevant literature for Metastatic Melanoma.
- reference: DOI:10.1371/journal.pgen.1007589
title: Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis
found_in:
- Metastatic_Melanoma-deep-research-falcon.md
findings:
- statement: Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis
supporting_text: Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis
- reference: DOI:10.20517/cdr.2023.150
title: Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers
found_in:
- Metastatic_Melanoma-deep-research-falcon.md
findings:
- statement: Melanoma still reaches thousands of new diagnoses per year, and its aggressiveness makes recovery challenging, especially for those with stage III/IV unresectable melanoma.
supporting_text: Melanoma still reaches thousands of new diagnoses per year, and its aggressiveness makes recovery challenging, especially for those with stage III/IV unresectable melanoma.
evidence:
- reference: DOI:10.20517/cdr.2023.150
reference_title: Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Melanoma still reaches thousands of new diagnoses per year, and its aggressiveness makes recovery challenging, especially for those with stage III/IV unresectable melanoma.
explanation: Deep research cited this publication as relevant literature for Metastatic Melanoma.
- reference: DOI:10.20517/cdr.2024.54
title: Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma
found_in:
- Metastatic_Melanoma-deep-research-falcon.md
findings:
- statement: Melanoma is the most aggressive form of skin cancer, characterized by a poor prognosis, and its incidence has risen rapidly over the past 30 years.
supporting_text: Melanoma is the most aggressive form of skin cancer, characterized by a poor prognosis, and its incidence has risen rapidly over the past 30 years.
evidence:
- reference: DOI:10.20517/cdr.2024.54
reference_title: Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Melanoma is the most aggressive form of skin cancer, characterized by a poor prognosis, and its incidence has risen rapidly over the past 30 years.
explanation: Deep research cited this publication as relevant literature for Metastatic Melanoma.
- reference: DOI:10.3389/fimmu.2024.1520441
title: 'The prognostic value of circulating tumor DNA in malignant melanoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis'
found_in:
- Metastatic_Melanoma-deep-research-falcon.md
findings:
- statement: Circulating tumor DNA (ctDNA) is an emerging biomarker in malignant melanoma(MM), and high levels of ctDNA may reflect a higher tumor load.
supporting_text: Circulating tumor DNA (ctDNA) is an emerging biomarker in malignant melanoma(MM), and high levels of ctDNA may reflect a higher tumor load.
evidence:
- reference: DOI:10.3389/fimmu.2024.1520441
reference_title: 'The prognostic value of circulating tumor DNA in malignant melanoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis'
supports: SUPPORT
evidence_source: OTHER
snippet: Circulating tumor DNA (ctDNA) is an emerging biomarker in malignant melanoma(MM), and high levels of ctDNA may reflect a higher tumor load.
explanation: Deep research cited this publication as relevant literature for Metastatic Melanoma.
- reference: DOI:10.3389/fonc.2024.1512942
title: Global, regional, and national burden of cutaneous malignant melanoma from 1990 to 2021 and prediction to 2045
found_in:
- Metastatic_Melanoma-deep-research-falcon.md
findings:
- statement: Cutaneous Malignant Melanoma (CMM) is a significant global health challenge.
supporting_text: Cutaneous Malignant Melanoma (CMM) is a significant global health challenge.
evidence:
- reference: DOI:10.3389/fonc.2024.1512942
reference_title: Global, regional, and national burden of cutaneous malignant melanoma from 1990 to 2021 and prediction to 2045
supports: SUPPORT
evidence_source: COMPUTATIONAL
snippet: Cutaneous Malignant Melanoma (CMM) is a significant global health challenge.
explanation: Deep research cited this publication as relevant literature for Metastatic Melanoma.
- reference: DOI:10.3390/biom15020269
title: Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It
found_in:
- Metastatic_Melanoma-deep-research-falcon.md
findings:
- statement: Resistance to anti-PD-1 therapy in melanoma remains a major obstacle in achieving effective and durable treatment outcomes, highlighting the need to understand and address the underlying mechanisms.
supporting_text: Resistance to anti-PD-1 therapy in melanoma remains a major obstacle in achieving effective and durable treatment outcomes, highlighting the need to understand and address the underlying mechanisms.
evidence:
- reference: DOI:10.3390/biom15020269
reference_title: Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It
supports: SUPPORT
evidence_source: OTHER
snippet: Resistance to anti-PD-1 therapy in melanoma remains a major obstacle in achieving effective and durable treatment outcomes, highlighting the need to understand and address the underlying mechanisms.
explanation: Deep research cited this publication as relevant literature for Metastatic Melanoma.
- reference: DOI:10.3390/biomedicines13010225
title: Advances in Immunotherapy and Targeted Therapy of Malignant Melanoma
found_in:
- Metastatic_Melanoma-deep-research-falcon.md
findings:
- statement: Malignant melanoma (MM) is a malignant tumor, resulting from mutations in melanocytes of the skin and mucous membranes.
supporting_text: Malignant melanoma (MM) is a malignant tumor, resulting from mutations in melanocytes of the skin and mucous membranes.
evidence:
- reference: DOI:10.3390/biomedicines13010225
reference_title: Advances in Immunotherapy and Targeted Therapy of Malignant Melanoma
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Malignant melanoma (MM) is a malignant tumor, resulting from mutations in melanocytes of the skin and mucous membranes.
explanation: Deep research cited this publication as relevant literature for Metastatic Melanoma.
- reference: DOI:10.3390/cancers15123224
title: New Approaches to Targeted Therapy in Melanoma
found_in:
- Metastatic_Melanoma-deep-research-falcon.md
findings:
- statement: It was just slightly more than a decade ago when metastatic melanoma carried a dismal prognosis with few, if any, effective therapies.
supporting_text: It was just slightly more than a decade ago when metastatic melanoma carried a dismal prognosis with few, if any, effective therapies.
evidence:
- reference: DOI:10.3390/cancers15123224
reference_title: New Approaches to Targeted Therapy in Melanoma
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: It was just slightly more than a decade ago when metastatic melanoma carried a dismal prognosis with few, if any, effective therapies.
explanation: Deep research cited this publication as relevant literature for Metastatic Melanoma.
- reference: DOI:10.3390/cancers16010101
title: 'Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective'
found_in:
- Metastatic_Melanoma-deep-research-falcon.md
findings:
- statement: The introduction of immunotherapy revolutionized the treatment landscape in metastatic melanoma.
supporting_text: The introduction of immunotherapy revolutionized the treatment landscape in metastatic melanoma.
evidence:
- reference: DOI:10.3390/cancers16010101
reference_title: 'Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: The introduction of immunotherapy revolutionized the treatment landscape in metastatic melanoma.
explanation: Deep research cited this publication as relevant literature for Metastatic Melanoma.
- reference: DOI:10.3390/cancers16081571
title: 'Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance'
found_in:
- Metastatic_Melanoma-deep-research-falcon.md
findings:
- statement: Melanoma is the most aggressive and deadly form of skin cancer due to its high propensity to metastasize to distant organs.
supporting_text: Melanoma is the most aggressive and deadly form of skin cancer due to its high propensity to metastasize to distant organs.
evidence:
- reference: DOI:10.3390/cancers16081571
reference_title: 'Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance'
supports: SUPPORT
evidence_source: OTHER
snippet: Melanoma is the most aggressive and deadly form of skin cancer due to its high propensity to metastasize to distant organs.
explanation: Deep research cited this publication as relevant literature for Metastatic Melanoma.
- reference: DOI:10.3390/cancers16142559
title: Efficacy of Ipilimumab and Nivolumab in Patients with Melanoma and Brain Metastases—A Danish Real-World Cohort
found_in:
- Metastatic_Melanoma-deep-research-falcon.md
findings:
- statement: Combination immunotherapy using ipilimumab/nivolumab is the golden standard treatment for patients with melanoma and asymptomatic brain metastases (MBM).
supporting_text: Combination immunotherapy using ipilimumab/nivolumab is the golden standard treatment for patients with melanoma and asymptomatic brain metastases (MBM).
evidence:
- reference: DOI:10.3390/cancers16142559
reference_title: Efficacy of Ipilimumab and Nivolumab in Patients with Melanoma and Brain Metastases—A Danish Real-World Cohort
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Combination immunotherapy using ipilimumab/nivolumab is the golden standard treatment for patients with melanoma and asymptomatic brain metastases (MBM).
explanation: Deep research cited this publication as relevant literature for Metastatic Melanoma.
- reference: DOI:10.3390/cancers18030382
title: 'Drug Therapy for Melanoma: Current Updates and Future Prospects'
found_in:
- Metastatic_Melanoma-deep-research-falcon.md
findings:
- statement: Melanoma was once considered ‘incurable’; however, drug therapy for the condition has dramatically transformed with the advent of immune checkpoint inhibitors and molecular targeted therapies.
supporting_text: Melanoma was once considered ‘incurable’; however, drug therapy for the condition has dramatically transformed with the advent of immune checkpoint inhibitors and molecular targeted therapies.
evidence:
- reference: DOI:10.3390/cancers18030382
reference_title: 'Drug Therapy for Melanoma: Current Updates and Future Prospects'
supports: SUPPORT
evidence_source: OTHER
snippet: Melanoma was once considered ‘incurable’; however, drug therapy for the condition has dramatically transformed with the advent of immune checkpoint inhibitors and molecular targeted therapies.
explanation: Deep research cited this publication as relevant literature for Metastatic Melanoma.
- reference: DOI:10.3390/cells13161383
title: Molecular Susceptibility and Treatment Challenges in Melanoma
found_in:
- Metastatic_Melanoma-deep-research-falcon.md
findings:
- statement: Melanoma is the most aggressive subtype of cancer, with a higher propensity to spread compared to most solid tumors.
supporting_text: Melanoma is the most aggressive subtype of cancer, with a higher propensity to spread compared to most solid tumors.
evidence:
- reference: DOI:10.3390/cells13161383
reference_title: Molecular Susceptibility and Treatment Challenges in Melanoma
supports: SUPPORT
evidence_source: OTHER
snippet: Melanoma is the most aggressive subtype of cancer, with a higher propensity to spread compared to most solid tumors.
explanation: Deep research cited this publication as relevant literature for Metastatic Melanoma.
- reference: DOI:10.3390/ijms251810120
title: 'Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?'
found_in:
- Metastatic_Melanoma-deep-research-falcon.md
findings:
- statement: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by enhancing anti-tumour immune responses, demonstrating significant efficacy in various malignancies, including melanoma.
supporting_text: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by enhancing anti-tumour immune responses, demonstrating significant efficacy in various malignancies, including melanoma.
evidence:
- reference: DOI:10.3390/ijms251810120
reference_title: 'Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by enhancing anti-tumour immune responses, demonstrating significant efficacy in various malignancies, including melanoma.
explanation: Deep research cited this publication as relevant literature for Metastatic Melanoma.
- reference: DOI:10.3892/mi.2024.137
title: Immune checkpoint inhibitors in metastatic melanoma therapy (Review)
found_in:
- Metastatic_Melanoma-deep-research-falcon.md
findings:
- statement: Immune checkpoint inhibitors in metastatic melanoma therapy (Review)
supporting_text: Immune checkpoint inhibitors in metastatic melanoma therapy (Review)
Definition/overview. Melanoma is a malignant neoplasm arising from melanocytes; metastatic melanoma refers to melanoma that has disseminated beyond the primary site/regional basin to distant organs (stage IV in common staging usage), or clinically “advanced/unresectable” disease requiring systemic therapy (wang2025advancesinimmunotherapy pages 1-2, datzmann2021implementationandeffectiveness pages 2-3). Metastatic disease commonly involves lung, liver, brain, lymph nodes, and bone (wang2025advancesinimmunotherapy pages 1-2). Historically, metastatic melanoma had extremely poor survival prior to modern systemic therapies (poletto2023predictivefactorsin pages 1-2, shah2024immunecheckpointinhibitors pages 1-2).
Key concept: treatment eras. Multiple 2023–2024 sources emphasize a treatment‑era shift: before immune checkpoint inhibitors (ICIs) and modern targeted therapy, median overall survival (OS) was ~6 months; contemporary regimens can yield multi‑year median OS and long‑term survival in a substantial fraction of patients (poletto2023predictivefactorsin pages 1-2, jalil2024exploringresistanceto pages 1-3).
Direct abstract quotes supporting key concepts (examples). - From a 2024 ICI‑focused review: “However, over 50% of patients experience limited or no response to ICI therapy. Resistance to ICIs is influenced by a complex interplay of tumour intrinsic and extrinsic factors.” (Hossain et al., 2024; https://doi.org/10.3390/ijms251810120) (hossain2024immunecheckpointinhibitor pages 1-2) - From a 2024 resistance review: metastatic melanoma survival “below 5%” historically, shifting to “over 50%” 5‑year survival in the modern era, with ~50% not responding or relapsing (Jalil et al., 2024; https://doi.org/10.20517/cdr.2024.54) (jalil2024exploringresistanceto pages 1-3)
UV radiation as dominant environmental carcinogen. Contemporary epidemiologic reviews identify ultraviolet radiation exposure as the key risk factor for cutaneous malignant melanoma, with additional contributions from phenotype and behavioral exposure patterns (sunburns, indoor tanning) (pinto2024globaltrendsin pages 7-11). Mechanistically, UV can generate DNA damage (e.g., thymine dimers), while melanin is protective via UV absorption and free‑radical scavenging (wang2025recentglobalpatterns pages 1-2).
Environmental/host risk factors (population literature). Risk factors highlighted in 2024 global trend and 2024 US mortality analyses include: UV exposure (strongest), fair skin phenotype and sun sensitivity, high nevus count/dysplastic nevi, family/personal history, immunosuppression, and indoor tanning (pinto2024globaltrendsin pages 7-11, didier2024patternsandtrends pages 1-2). Ozone depletion and geography influence UV exposure and melanoma burden (pinto2024globaltrendsin pages 7-11).
Genetic susceptibility / molecular predisposition (tumor drivers). Metastatic melanoma biology is strongly shaped by somatic driver alterations that activate the MAPK pathway. Reviews cite BRAFV600 mutations in ~40–50% of cutaneous melanomas, enabling BRAF/MEK targeted therapy (fernandez2023newapproachesto pages 1-3, jalil2024exploringresistanceto pages 1-3).
Protective pigmentation context. Higher melanin levels reduce UV penetration and associated damage; lower melanin in lighter-skinned individuals increases melanoma risk (wang2025recentglobalpatterns pages 1-2). (Specific quantified effect sizes for sunscreen or behavioral interventions were not retrieved in current tool evidence.)
The retrieved evidence supports a conceptual model in which UV exposure induces DNA damage and mutational/neoantigen landscapes that influence immune recognition and response to immunotherapy (high mutational burden is repeatedly discussed as a predictor of ICI response), linking environmental carcinogenesis to immunotherapy sensitivity (kato2026drugtherapyfor pages 3-4, roccuzzo2024prognosticbiomarkersin pages 3-4). (Specific GxE loci/effect sizes were not retrieved in current tool evidence.)
Metastatic dissemination sites. Advanced melanoma commonly metastasizes to lung, liver, brain, lymph nodes, and bone (wang2025advancesinimmunotherapy pages 1-2). Brain metastases are frequent; one real‑world community series observed brain metastases in 27.4% (20/73) during first‑line ipilimumab+nivolumab management, and the paper reiterates historical estimates of very high lifetime risk in metastatic melanoma (ong2025timingofbrain pages 1-2, ong2025timingofbrain pages 4-5).
Treatment-related phenotypes (immune-related toxicities). Combination ICI improves efficacy but increases high‑grade toxicity, a recurring expert theme in 2023–2024 reviews (hossain2024immunecheckpointinhibitor pages 1-2). In a Danish real‑world cohort of asymptomatic melanoma brain metastases treated with ipilimumab+nivolumab, 35.4% discontinued due to grade 3–4 adverse events (kattenhøj2024efficacyofipilimumab pages 4-6).
Because phenotype frequency tables were not retrieved from dedicated phenotype resources (HPO/Orphanet/OMIM) in the tool context, the following HPO term suggestions are plausible mappings for knowledge‑base structuring (not asserted as comprehensive): - Brain metastasis: Metastatic neoplasm (HP:0030972) + site qualifiers; consider custom mapping to “brain metastasis” if available in HPO extensions. - Liver metastasis: Metastatic neoplasm (HP:0030972) with liver localization. - Elevated LDH: Increased circulating lactate dehydrogenase concentration (HPO term exists in many HPO builds; exact ID not retrieved here). - Cutaneous/subcutaneous metastases: Subcutaneous nodule (HP:0012126) (as an approximation).
(For a production knowledge base, direct HPO lookups are recommended; not possible in this run due to tool limitations.)
MAPK pathway driver alterations. Reviews consistently emphasize MAPK pathway activation as central. Key genes/targets implicated in metastatic melanoma and therapy selection include BRAF, MAP2K1/2 (MEK1/2), and NRAS; immune checkpoint targets include PDCD1 (PD‑1) and CTLA4 (OpenTargets Search: metastatic melanoma, fernandez2023newapproachesto pages 1-3). BRAF alterations are the most established predictive biomarker for targeted therapy selection (fernandez2023newapproachesto pages 1-3).
(Allele frequencies in population databases and ClinVar/ACMG germline classifications were not retrieved in current evidence. For metastatic melanoma, most clinical decision-making is based on somatic tumor profiling.)
Tumor mutational burden (TMB), PD‑L1, and IFN‑γ signatures. A 2024 biomarker review highlights TMB, PD‑L1 expression, and IFN‑γ signature as promising correlates of improved response in melanoma trials (roccuzzo2024prognosticbiomarkersin pages 3-4). Another 2023 review frames biomarkers across host/immune/tumor categories and emphasizes LDH/CRP/ctDNA plus inflammatory signatures (poletto2023predictivefactorsin pages 1-2).
Circulating tumor DNA (ctDNA). A meta‑analysis including 1,063 melanoma patients treated with ICIs (literature through Aug 15, 2024) found detectable ctDNA was associated with substantially worse outcomes: - Pretreatment detectable ctDNA: OS HR 3.19; PFS HR 2.08. - On‑treatment detectable ctDNA: OS HR 4.57; PFS HR 3.79. (liu2025theprognosticvalue pages 1-2)
1) UV exposure / DNA damage → mutational accumulation → oncogenic signaling activation (MAPK pathway via BRAF/NRAS/NF1 alterations) → melanocyte transformation and tumor progression (wang2025recentglobalpatterns pages 1-2, fernandez2023newapproachesto pages 1-3). 2) Tumor evolution and microenvironmental shaping → immune escape (PD‑1/PD‑L1 axis, CTLA‑4 mediated suppression, myeloid-driven immunosuppression) → metastatic progression and therapeutic resistance (song2024currentknowledgeabout pages 1-3, zielinska2025mechanismsofresistance pages 8-9).
MAPK pathway (RAS–RAF–MEK–ERK). Central melanoma growth and survival pathway; BRAF mutations enable targeted inhibitors. Acquired resistance often involves MAPK reactivation (fateeva2024currentstateof pages 5-6).
PI3K–AKT pathway bypass and crosstalk. Resistance and survival can be supported by PI3K–AKT signaling; NF1/PTEN alterations are discussed as enabling this bypass and contributing to targeted therapy resistance (kolathur2024molecularsusceptibilityand pages 13-15, kato2026drugtherapyfor pages 3-4).
Immune evasion and TME suppression. Resistance to anti‑PD‑1 can be mediated by suppressive TME cell types (Tregs, TAMs, MDSCs), suppressive cytokines (IL‑10, TGF‑β), nutrient depletion (arginine/tryptophan), hypoxia/acidity, and IDO‑mediated tryptophan catabolism (zielinska2025mechanismsofresistance pages 8-9). Microbiome influences anti‑PD‑1 response, with some taxa associated with enhanced dendritic cell activity (zielinska2025mechanismsofresistance pages 8-9).
Visual evidence (treatment landscape and resistance). Fateeva et al. (2024) provide a schematic overview of FDA‑approved advanced melanoma therapies (ICIs and targeted BRAF/MEK agents) and a separate figure outlining targeted‑therapy resistance mechanisms including MAPK reactivation/bypass (fateeva2024currentstateof media 7006da46, fateeva2024currentstateof media e15bcd35).
Organ-level metastatic targets. Lung, liver, brain, lymph nodes, bone are repeatedly cited common metastatic destinations (wang2025advancesinimmunotherapy pages 1-2). Brain metastasis is clinically prominent and a major determinant of management strategy (kattenhøj2024efficacyofipilimumab pages 1-2).
UBERON suggestions (examples; IDs not retrieved here): skin; lymph node; brain; liver; lung; bone.
Staging concept. Real-world cohort definitions tie distant metastatic codes (C78/C79) to UICC/AJCC stage IV, and locoregional metastases (C77) to stage III in study classification (datzmann2021implementationandeffectiveness pages 2-3). Clinically, metastatic melanoma may present synchronously with initial diagnosis or metachronously (subsequent metastasis), as operationalized in registry analyses (datzmann2021implementationandeffectiveness pages 2-3).
Brain metastasis timing. In a community cohort on first‑line ipilimumab+nivolumab, delayed brain metastases were uncommon (6/59) and occurred within 15 months, with poor outcomes (ong2025timingofbrain pages 1-2).
US CDC WONDER analysis (1999–2020): 184,416 melanoma deaths; age‑adjusted mortality declined from 2.7 to 2.0 per 100,000, with higher mortality in men and older adults; rural populations had higher mortality than urban/suburban (didier2024patternsandtrends pages 1-2).
Standard-of-care diagnosis (high-level). The tool evidence set in this run did not include dedicated pathology/imaging guideline documents; therefore, detailed diagnostic criteria, histopathologic and immunohistochemical panels, and radiology protocols are not exhaustively enumerated here.
Real-world implementation signal (testing/monitoring). Danish national practice for melanoma brain metastases in a registry cohort used MRI for intracranial response and PET/CT for systemic disease at ~12-week intervals during early follow-up, consistent with high-intensity monitoring in advanced melanoma care (kattenhøj2024efficacyofipilimumab pages 4-6).
Biomarker testing. BRAF mutation status is described as a key predictive biomarker for therapy selection; TMB is described as controversial; ctDNA is emerging as prognostic/monitoring biomarker with meta-analytic hazard ratios (fernandez2023newapproachesto pages 1-3, liu2025theprognosticvalue pages 1-2).
A 2023 review summarizes historical and modern outcomes: - Pre‑modern era: metastatic melanoma median OS ~6 months (poletto2023predictivefactorsin pages 1-2). - Anti‑PD‑1 monotherapy: ORR 42–45%; median OS ~3 years (poletto2023predictivefactorsin pages 1-2). - Nivolumab + ipilimumab: ORR 58%; median OS 72.1 months (poletto2023predictivefactorsin pages 1-2). A 2024 resistance review cites CheckMate‑067 long‑term data: median OS 72.1 months and 6.5‑year survival 56% (jalil2024exploringresistanceto pages 1-3).
LDH risk stratification. A 2024 biomarker review reports dramatic stratification by LDH: LDH <2×ULN associated with 1‑year PFS 68% and OS 90%, whereas LDH ≥2×ULN shows 1‑year PFS 8% and OS 40% (roccuzzo2024prognosticbiomarkersin pages 3-4).
ctDNA hazard ratios. Detectable ctDNA is associated with markedly worse OS and PFS both pre‑treatment and during ICI therapy (liu2025theprognosticvalue pages 1-2).
Immune checkpoint inhibitors (ICIs). ICIs target CTLA‑4 and PD‑1/PD‑L1 (and newer targets such as LAG‑3) to restore anti-tumor T cell activity (shah2024immunecheckpointinhibitors pages 1-2, hossain2024immunecheckpointinhibitor pages 1-2). Combination strategies improve efficacy but can increase toxicity (hossain2024immunecheckpointinhibitor pages 1-2).
Targeted therapy for BRAF‑mutant melanoma. BRAF inhibitors plus MEK inhibitors improve response and survival versus earlier approaches but are limited by resistance (often within months) and toxicity (fateeva2024currentstateof pages 5-6).
Visual summary of therapy classes. Fateeva et al. (2024) figure depicts FDA-approved advanced melanoma therapies across ICI classes and BRAF/MEK targeted agents (fateeva2024currentstateof media 7006da46).
Real-world outcomes with ipilimumab+nivolumab in asymptomatic melanoma brain metastases. Danish registry cohort (n=79) first‑line ipilimumab+nivolumab: ORR 46.9%, CR 16.5%, 6‑month PFS 53.5%, median PFS 6.5 months, median OS not reached at 5 years (kattenhøj2024efficacyofipilimumab pages 1-2).
Trial benchmark and emerging combinations. A 2024 Neuro-Oncology Advances abstract cites CheckMate 204 intracranial response 54% with ipilimumab+nivolumab and grade 3/4 TRAEs 55%, and early phase II data for nivolumab+relatlimab in brain metastases (intracranial response 43% in first 8 patients; grade 3 TRAEs 12%) (phillips2024imun05phaseii pages 1-1).
ClinicalTrials.gov records provide structured evidence for near-term implementations: - RELATIVITY-047 (NCT03470922): relatlimab+nivolumab vs nivolumab, Phase 2/3; primary endpoint PFS by blinded review; includes biomarker tissue requirements; excludes active brain metastases (NCT03470922 chunk 1). - RELATIVITY-127 (NCT05625399): SC vs IV nivolumab+relatlimab FDC, Phase 3; primary endpoints pharmacokinetics with key clinical endpoints including ORR/PFS/OS and QoL (FACT‑MS) (NCT05625399 chunk 1). - TILVANCE-301 / IOV-MEL-301 (NCT05727904): autologous TIL therapy lifileucel + pembrolizumab vs pembrolizumab, Phase 3; primary endpoints ORR and PFS; includes optional crossover to lifileucel upon progression (NCT05727904 chunk 1).
Primary prevention. Global trend analyses emphasize UV exposure as the primary modifiable risk factor and connect prevention (sun protection) and early detection to mortality declines in high-income regions (e.g., Australia) (pinto2024globaltrendsin pages 1-2, pinto2024globaltrendsin pages 7-11).
Secondary prevention/early detection. The global trends review highlights early diagnosis (including dermoscopy and ABCD rule awareness) as contributors to improved outcomes and mortality reductions (pinto2024globaltrendsin pages 7-11).
(Quantified effect sizes for specific screening programs or sunscreen interventions were not retrieved in the current tool evidence.)
Canine melanoma as a comparative model. Integrated comparative genomic analysis of canine malignant melanoma identifies recurrent somatic alterations (e.g., truncating PTPRJ mutations ~19%; RAS mutations ~24%; TP53 mutations ~19%; MDM2 amplifications ~24%), with noted differences such as absent BRAF mutations and low UV mutational signatures, supporting comparative modeling for BRAF‑wild-type/sun‑shielded melanoma subtypes (Hendricks et al., 2018; https://doi.org/10.1371/journal.pgen.1007589) (pqac-000000?? not retrieved in evidence extraction in this run; paper text present but not gathered into evidence snippets).
Because full evidence snippets were not extracted for this section in the current run, cross‑species claims should be treated as incomplete.
The current tool evidence set did not include dedicated model-organism or cell-line methodological reviews for metastatic melanoma; thus only high-level, commonly used systems are listed as non‑exhaustive: genetically engineered mouse models (BRAF/NRAS-driven), xenografts/PDX, syngeneic mouse melanoma lines, and TIL/immune co-culture systems. For a knowledge base, these should be populated using model‑system databases (MGI/IMSR/Cellosaurus) and primary experimental papers.
| Domain | Finding | Numeric value(s) | Source (first author year) | URL | Evidence ID |
|---|---|---|---|---|---|
| Epidemiology/Burden | Global melanoma incidence and deaths (GLOBOCAN 2022) | 331,722 new melanoma cases; ~58,667 deaths worldwide | Wang 2025 | https://doi.org/10.1097/cm9.0000000000003416 | (wang2025recentglobalpatterns pages 1-2) |
| Epidemiology/Burden | Global cutaneous malignant melanoma burden (GBD 2021) | Prevalence 833,215 cases in 2021; ASPR 25.37/100,000; ASMR 0.73/100,000; DALYs 1,678,836 | Liu 2024 | https://doi.org/10.3389/fonc.2024.1512942 | (liu2024globalregionaland pages 1-2) |
| Epidemiology/Burden | US melanoma mortality trend, 1999–2020 | 184,416 deaths; age-adjusted mortality rate declined 2.7 to 2.0/100,000; APC -1.3%/year; after 2013 non-Hispanic White AAMR -6.1%/year | Didier 2024 | https://doi.org/10.1186/s12885-024-12426-z | (didier2024patternsandtrends pages 1-2) |
| Therapy Outcomes | Historical metastatic melanoma prognosis before modern therapy | Median OS ~6 months; 1-year OS ~25% | Shah 2024 | https://doi.org/10.3892/mi.2024.137 | (shah2024immunecheckpointinhibitors pages 1-2) |
| Therapy Outcomes | Historical metastatic melanoma prognosis before 2011 | Median OS about 6 months | Poletto 2023 | https://doi.org/10.3390/cancers16010101 | (poletto2023predictivefactorsin pages 1-2) |
| Therapy Outcomes | Anti-PD-1 monotherapy outcomes in metastatic melanoma | ORR 42–45%; median PFS 4.6–8.4 months; median OS around 3 years | Poletto 2023 | https://doi.org/10.3390/cancers16010101 | (poletto2023predictivefactorsin pages 1-2) |
| Therapy Outcomes | Nivolumab + ipilimumab combination outcomes | ORR 58%; median PFS 11.5 months; median OS 72.1 months | Poletto 2023 | https://doi.org/10.3390/cancers16010101 | (poletto2023predictivefactorsin pages 1-2) |
| Therapy Outcomes | Nivolumab + ipilimumab long-term survival | 6.5-year survival rate 56% | Jalil 2024 | https://doi.org/10.20517/cdr.2024.54 | (jalil2024exploringresistanceto pages 1-3) |
| Therapy Outcomes | BRAF+MEK targeted therapy outcomes in advanced melanoma | Overall response and survival rates increased to 50–70%; progression often after 6–7 months with single-agent BRAFi | Fateeva 2024 | https://doi.org/10.3390/cancers16081571 | (fateeva2024currentstateof pages 5-6) |
| Therapy Outcomes | Real-world asymptomatic melanoma brain metastases treated first-line with ipi+nivo | ORR 46.9%; CR 16.5%; 6-month PFS 53.5%; median PFS 6.5 months; median OS not reached at 5 years | Kattenhøj 2024 | https://doi.org/10.3390/cancers16142559 | (kattenhøj2024efficacyofipilimumab pages 1-2) |
| Therapy Outcomes | ctDNA prognostic impact before ICI | OS HR 3.19 (95% CI 2.22–4.58); PFS HR 2.08 (95% CI 1.61–2.69) for detectable pretreatment ctDNA | Liu 2025 | https://doi.org/10.3389/fimmu.2024.1520441 | (liu2025theprognosticvalue pages 1-2) |
| Therapy Outcomes | ctDNA prognostic impact during ICI | OS HR 4.57 (95% CI 3.03–6.91); PFS HR 3.79 (95% CI 2.13–6.75) for detectable on-treatment ctDNA | Liu 2025 | https://doi.org/10.3389/fimmu.2024.1520441 | (liu2025theprognosticvalue pages 1-2) |
| Therapy Outcomes | LDH-stratified survival with metastatic melanoma therapy | LDH <2x ULN: 1-year PFS 68%, OS 90%; 2-year PFS 46%, OS 75%. LDH ≥2x ULN: 1-year PFS 8%, OS 40%; 2-year PFS 2%, OS 7% | Roccuzzo 2024 | https://doi.org/10.1080/14737159.2024.2347484 | (roccuzzo2024prognosticbiomarkersin pages 3-4) |
| Ongoing Clinical Trials | RELATIVITY-047 (NCT03470922): relatlimab + nivolumab vs nivolumab in untreated unresectable/metastatic melanoma | Phase 2/3; ACTIVE_NOT_RECRUITING; enrollment 714; start 2018-04-11; primary endpoint PFS by BICR per RECIST v1.1; key secondary endpoints OS, ORR | Bristol-Myers Squibb / NCT03470922 | https://clinicaltrials.gov/study/NCT03470922 | (NCT03470922 chunk 1) |
| Ongoing Clinical Trials | RELATIVITY-127 (NCT05625399): SC vs IV nivolumab + relatlimab fixed-dose combination in previously untreated metastatic/unresectable melanoma | Phase 3; ACTIVE_NOT_RECRUITING; enrollment 579; start 2023-03-06; primary endpoints nivolumab and relatlimab PK (Cavgd28, Cminss); key secondary endpoints ORR, DoR, DCR, TTR, PFS, OS, safety, FACT-MS | Bristol-Myers Squibb / NCT05625399 | https://clinicaltrials.gov/study/NCT05625399 | (NCT05625399 chunk 1) |
| Ongoing Clinical Trials | TILVANCE-301 / IOV-MEL-301 (NCT05727904): lifileucel + pembrolizumab vs pembrolizumab alone in untreated advanced melanoma | Phase 3; RECRUITING; enrollment 670; start 2023-03-30; primary endpoints ORR and PFS by blinded independent review per RECIST v1.1; key secondary endpoints OS, CR rate, DoR, EFS, PFS2, safety | Iovance / NCT05727904 | https://clinicaltrials.gov/study/NCT05727904 | (NCT05727904 chunk 1) |
Table: This table compiles high-yield quantitative findings for metastatic melanoma across epidemiology, therapy outcomes, biomarker prognostics, and major ongoing clinical trials. It is useful as a compact reference for evidence-backed burden estimates and current treatment landscape metrics.
1) Durable survival is now achievable, especially with combination ICI regimens, but primary/acquired resistance remains common (~50%) (poletto2023predictivefactorsin pages 1-2, jalil2024exploringresistanceto pages 1-3, hossain2024immunecheckpointinhibitor pages 1-2). 2) Mechanisms of resistance are multi-layered, spanning tumor intrinsic (antigen presentation defects, IFN‑γ pathway changes, MAPK/PI3K signaling) and extrinsic TME factors (Tregs/TAMs/MDSCs, hypoxia/acidity, metabolic suppression), and may be influenced by the gut microbiome (kato2026drugtherapyfor pages 3-4, zielinska2025mechanismsofresistance pages 8-9). 3) Real-world data support translation of trial efficacy to selected populations (e.g., asymptomatic melanoma brain metastases treated with ipilimumab+nivolumab in a nationwide Danish registry) (kattenhøj2024efficacyofipilimumab pages 1-2). 4) Biomarkers with practical clinical traction include LDH and ctDNA, with strong prognostic separation and meta-analytic hazard ratios, while TMB/PD‑L1/IFN‑γ signatures are promising but require standardization and context-aware interpretation (roccuzzo2024prognosticbiomarkersin pages 3-4, liu2025theprognosticvalue pages 1-2).
References
(OpenTargets Search: metastatic melanoma): Open Targets Query (metastatic melanoma, 43 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(datzmann2021implementationandeffectiveness pages 2-3): T Datzmann, J Schmitt, S Fuhrmann, and M Roessler. Implementation and effectiveness of novel therapeutic substances for advanced malignant melanoma in saxony, germany, 2010–2020—cohort study …. Unknown journal, 2021.
(kattenhøj2024efficacyofipilimumab pages 1-2): Karoline Dreyer Kattenhøj, Christine Louise Møberg, Louise Mahncke Guldbrandt, Rasmus Blechingberg Friis, Christophe Kamungu Mapendano, Søren Kjær Petersen, Christina Halgaard Bruvik Ruhlmann, Inge Marie Svane, Marco Donia, Eva Ellebaek, and Henrik Schmidt. Efficacy of ipilimumab and nivolumab in patients with melanoma and brain metastases—a danish real-world cohort. Cancers, 16:2559, Jul 2024. URL: https://doi.org/10.3390/cancers16142559, doi:10.3390/cancers16142559. This article has 6 citations.
(jalil2024exploringresistanceto pages 1-3): Anum Jalil, Melissa M Donate, and Jane Mattei. Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma. Cancer Drug Resistance, Oct 2024. URL: https://doi.org/10.20517/cdr.2024.54, doi:10.20517/cdr.2024.54. This article has 17 citations.
(liu2024globalregionaland pages 1-2): Chengling Liu, Xingchen Liu, Li Hu, Xin Li, Haiming Xin, and Sailin Zhu. Global, regional, and national burden of cutaneous malignant melanoma from 1990 to 2021 and prediction to 2045. Frontiers in Oncology, Dec 2024. URL: https://doi.org/10.3389/fonc.2024.1512942, doi:10.3389/fonc.2024.1512942. This article has 25 citations.
(NCT05727904 chunk 1): Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.. Iovance Biotherapeutics, Inc.. 2023. ClinicalTrials.gov Identifier: NCT05727904
(wang2025advancesinimmunotherapy pages 1-2): Xue Wang, Shanshan Ma, Shuting Zhu, Liucun Zhu, and Wenna Guo. Advances in immunotherapy and targeted therapy of malignant melanoma. Biomedicines, 13:225, Jan 2025. URL: https://doi.org/10.3390/biomedicines13010225, doi:10.3390/biomedicines13010225. This article has 23 citations.
(poletto2023predictivefactorsin pages 1-2): Stefano Poletto, Luca Paruzzo, Alessandro Nepote, Daniela Caravelli, Dario Sangiolo, and Fabrizio Carnevale-Schianca. Predictive factors in metastatic melanoma treated with immune checkpoint inhibitors: from clinical practice to future perspective. Cancers, 16:101, Dec 2023. URL: https://doi.org/10.3390/cancers16010101, doi:10.3390/cancers16010101. This article has 16 citations.
(shah2024immunecheckpointinhibitors pages 1-2): Vedant Shah, Viraj Panchal, Abhi Shah, Bhavya Vyas, Siddharth Agrawal, and Sanket Bharadwaj. Immune checkpoint inhibitors in metastatic melanoma therapy (review). Medicine International, Feb 2024. URL: https://doi.org/10.3892/mi.2024.137, doi:10.3892/mi.2024.137. This article has 41 citations.
(hossain2024immunecheckpointinhibitor pages 1-2): Sultana Mehbuba Hossain, Kevin Ly, Yih Jian Sung, Antony Braithwaite, and Kunyu Li. Immune checkpoint inhibitor therapy for metastatic melanoma: what should we focus on to improve the clinical outcomes? International Journal of Molecular Sciences, 25:10120, Sep 2024. URL: https://doi.org/10.3390/ijms251810120, doi:10.3390/ijms251810120. This article has 11 citations.
(pinto2024globaltrendsin pages 7-11): Giuseppe De Pinto, Silvia Mignozzi, Carlo La Vecchia, Fabio Levi, Eva Negri, and Claudia Santucci. Global trends in cutaneous malignant melanoma incidence and mortality. Melanoma Research, 34:265-275, Feb 2024. URL: https://doi.org/10.1097/cmr.0000000000000959, doi:10.1097/cmr.0000000000000959. This article has 65 citations and is from a peer-reviewed journal.
(wang2025recentglobalpatterns pages 1-2): Mingyue Wang, Xinghua Gao, and Li Zhang. Recent global patterns in skin cancer incidence, mortality, and prevalence. Chinese Medical Journal, 138:185-192, Dec 2025. URL: https://doi.org/10.1097/cm9.0000000000003416, doi:10.1097/cm9.0000000000003416. This article has 131 citations and is from a peer-reviewed journal.
(didier2024patternsandtrends pages 1-2): Alexander J. Didier, Swamroop V. Nandwani, Dean Watkins, Alan M. Fahoury, Andrew Campbell, Daniel J. Craig, Divya Vijendra, and Nancy Parquet. Patterns and trends in melanoma mortality in the united states, 1999–2020. BMC Cancer, Jul 2024. URL: https://doi.org/10.1186/s12885-024-12426-z, doi:10.1186/s12885-024-12426-z. This article has 38 citations and is from a peer-reviewed journal.
(fernandez2023newapproachesto pages 1-3): Manuel Felipe Fernandez, Jacob Choi, and Jeffrey Sosman. New approaches to targeted therapy in melanoma. Cancers, 15:3224, Jun 2023. URL: https://doi.org/10.3390/cancers15123224, doi:10.3390/cancers15123224. This article has 48 citations.
(kato2026drugtherapyfor pages 3-4): Hiroshi Kato. Drug therapy for melanoma: current updates and future prospects. Cancers, 18:382, Jan 2026. URL: https://doi.org/10.3390/cancers18030382, doi:10.3390/cancers18030382. This article has 1 citations.
(roccuzzo2024prognosticbiomarkersin pages 3-4): Gabriele Roccuzzo, Cristina Sarda, Valentina Pala, Simone Ribero, and Pietro Quaglino. Prognostic biomarkers in melanoma: a 2023 update from clinical trials in different therapeutic scenarios. Expert Review of Molecular Diagnostics, 24:379-392, May 2024. URL: https://doi.org/10.1080/14737159.2024.2347484, doi:10.1080/14737159.2024.2347484. This article has 12 citations and is from a peer-reviewed journal.
(ong2025timingofbrain pages 1-2): Claire Victoria Ong and Wolfram Samlowski. Timing of brain metastases in relation to outcome during first-line ipilimumab plus nivolumab therapy for metastatic melanoma in a community oncology practice. Journal of Neuro-Oncology, 172:645-653, Feb 2025. URL: https://doi.org/10.1007/s11060-025-04951-z, doi:10.1007/s11060-025-04951-z. This article has 1 citations and is from a peer-reviewed journal.
(ong2025timingofbrain pages 4-5): Claire Victoria Ong and Wolfram Samlowski. Timing of brain metastases in relation to outcome during first-line ipilimumab plus nivolumab therapy for metastatic melanoma in a community oncology practice. Journal of Neuro-Oncology, 172:645-653, Feb 2025. URL: https://doi.org/10.1007/s11060-025-04951-z, doi:10.1007/s11060-025-04951-z. This article has 1 citations and is from a peer-reviewed journal.
(kattenhøj2024efficacyofipilimumab pages 4-6): Karoline Dreyer Kattenhøj, Christine Louise Møberg, Louise Mahncke Guldbrandt, Rasmus Blechingberg Friis, Christophe Kamungu Mapendano, Søren Kjær Petersen, Christina Halgaard Bruvik Ruhlmann, Inge Marie Svane, Marco Donia, Eva Ellebaek, and Henrik Schmidt. Efficacy of ipilimumab and nivolumab in patients with melanoma and brain metastases—a danish real-world cohort. Cancers, 16:2559, Jul 2024. URL: https://doi.org/10.3390/cancers16142559, doi:10.3390/cancers16142559. This article has 6 citations.
(fateeva2024currentstateof pages 5-6): Anna Fateeva, Kevinn Eddy, and Suzie Chen. Current state of melanoma therapy and next steps: battling therapeutic resistance. Cancers, 16:1571, Apr 2024. URL: https://doi.org/10.3390/cancers16081571, doi:10.3390/cancers16081571. This article has 53 citations.
(kolathur2024molecularsusceptibilityand pages 13-15): Kiran Kumar Kolathur, Radhakanta Nag, Prathvi V Shenoy, Yagya Malik, Sai Manasa Varanasi, Ramcharan Singh Angom, and Debabrata Mukhopadhyay. Molecular susceptibility and treatment challenges in melanoma. Cells, 13:1383, Aug 2024. URL: https://doi.org/10.3390/cells13161383, doi:10.3390/cells13161383. This article has 11 citations.
(liu2025theprognosticvalue pages 1-2): Lei Liu, Shufu Hou, Aiping Zhu, Bing Yan, Linchuan Li, and Dandan Song. The prognostic value of circulating tumor dna in malignant melanoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Frontiers in Immunology, Jan 2025. URL: https://doi.org/10.3389/fimmu.2024.1520441, doi:10.3389/fimmu.2024.1520441. This article has 9 citations and is from a peer-reviewed journal.
(song2024currentknowledgeabout pages 1-3): Lanni Song, Yixin Yang, and Xuechen Tian. Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers. Cancer Drug Resistance, May 2024. URL: https://doi.org/10.20517/cdr.2023.150, doi:10.20517/cdr.2023.150. This article has 5 citations.
(zielinska2025mechanismsofresistance pages 8-9): Magdalena K. Zielińska, Magdalena Ciążyńska, Dorota Sulejczak, Piotr Rutkowski, and Anna M. Czarnecka. Mechanisms of resistance to anti-pd-1 immunotherapy in melanoma and strategies to overcome it. Biomolecules, 15:269, Feb 2025. URL: https://doi.org/10.3390/biom15020269, doi:10.3390/biom15020269. This article has 28 citations.
(fateeva2024currentstateof media 7006da46): Anna Fateeva, Kevinn Eddy, and Suzie Chen. Current state of melanoma therapy and next steps: battling therapeutic resistance. Cancers, 16:1571, Apr 2024. URL: https://doi.org/10.3390/cancers16081571, doi:10.3390/cancers16081571. This article has 53 citations.
(fateeva2024currentstateof media e15bcd35): Anna Fateeva, Kevinn Eddy, and Suzie Chen. Current state of melanoma therapy and next steps: battling therapeutic resistance. Cancers, 16:1571, Apr 2024. URL: https://doi.org/10.3390/cancers16081571, doi:10.3390/cancers16081571. This article has 53 citations.
(phillips2024imun05phaseii pages 1-1): Suzanne Phillips, Elizabeth Burton, Isabella Claudia Glitza Oliva, Jennifer McQuade, Rodabe Amaria, Adi Diab, Michael Wong, Caroline Chung, Denái Milton, Jared Malke, Julie Simon, Jeffrey Wefel, Jing Li, Michael Davies, and Hussein Tawbi. Imun-05 phase ii study of nivolumab (nivo) in combination with relatlimab (rela) in patients with active melanoma brain metastases (mbm). Neuro-Oncology Advances, 6:i14-i15, Aug 2024. URL: https://doi.org/10.1093/noajnl/vdae090.044, doi:10.1093/noajnl/vdae090.044. This article has 1 citations and is from a peer-reviewed journal.
(NCT03470922 chunk 1): A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma. Bristol-Myers Squibb. 2018. ClinicalTrials.gov Identifier: NCT03470922
(NCT05625399 chunk 1): A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma. Bristol-Myers Squibb. 2023. ClinicalTrials.gov Identifier: NCT05625399
(pinto2024globaltrendsin pages 1-2): Giuseppe De Pinto, Silvia Mignozzi, Carlo La Vecchia, Fabio Levi, Eva Negri, and Claudia Santucci. Global trends in cutaneous malignant melanoma incidence and mortality. Melanoma Research, 34:265-275, Feb 2024. URL: https://doi.org/10.1097/cmr.0000000000000959, doi:10.1097/cmr.0000000000000959. This article has 65 citations and is from a peer-reviewed journal.